AHF: ‘Gilead: We Told You So on COVID Drug Pricing!’

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Aug 04, 2020 07:27 pm
WASHINGTON -- 

AIDS Healthcare Foundation (AHF) today praised the 34 state attorneys general for taking action to bring down the cost and increase the supply of Gilead Sciences’ remdesivir, the only approved treatment for COVID-19, the novel coronavirus.

“The August 4 letter from the attorneys general basically echoes and implements what AHF has been saying since as far back as March 30, that since taxpayers paid for the research and development—and are now paying for the production of this essential medicine—the price should be reasonable,” said Tom Myers, general counsel and chief of public affairs for AHF.

In May, Gilead, which developed the drug years earlier (with as much as $70 million in government research and development funding) as a possible Ebola treatment, announced that it would set the price for remdesivir between $2,300 and $3,100 per patient for a five-day course of treatment. AHF issued a statement demanding that Gilead price the drug at no more than one dollar per day.

AHF’s dollar per dose demand is based on a University of Liverpool research study, “Minimum costs to manufacture new treatments for COVID-19,” that allows for recovery of the cost of manufacturing plus a reasonable profit.

“We applaud these state elected officials for standing up to Gilead’s greed and thank them for taking this action,” added John Hassell, national advocacy director for AHF.

About AIDS Healthcare Foundation (AHF)

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 1.4 million people in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare.

MEDIA CONTACTS:

Ged Kenslea, Senior Director, Communications, AHF
+1.323.791.5526 [cell]
+.323.308.1833 [work]
[email protected]

John Hassell, National Director of Advocacy, AHF
+1.202.774.4854 [cell]
[email protected]

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).